Mesalazine and the prevention of colorectal cancer in inflammatory bowel disease

摘要

Inflammatory bowel disease (IBD) patients have an increased risk of developing colorectal cancer (CRC). The risk depends on disease duration, extent of inflammation, presence of primary sclerosing cholangitis, a positive family history of CRC, age of onset and the degree of endoscopic and histological activity1. Furthermore, CRC accounts for about 15% of deaths related to IBD; however, IBD-related colorectal carcinoma accounts for only 1-2% of all cases of CRC.